Robert Paull
Advisor @ Exponential
About
Robert is Co-Founder and Venture Partner at Lux Capital Management, focusing on healthcare. Robert manages Lux's investments in Cala Health (neuroperipherals) and Kyruus (healthcare IT). Previous investments include Visterra, Inc. (acquired by Otsuka - infectious diseases), Cerulean Pharmaceuticals (NASDAQ: CERU – pharmaceutical nanoencapsulation), Magen Biosciences (acquired by PPD – dermatology), and Molecular Imprints (acquired by Canon – semiconductor imprint lithography). Robert is also an Advisor to Zelda Ventures, Sabanci Climate Ventures, Outsized Ventures, and mentor at KidsX (pediatric health startup accelerator). Robert was previously advisor to Appa Health (adolescent mental health), Broken String Biosciences Ltd and the President of documentary film company MacGillivray Freeman Films. Robert was the founding CEO of Mahana Therapeutics (digital therapeutics), founding CEO of Harvard Medical School spinout Genocea Biosciences (NASDAQ: GNCA - vaccines) and founding CEO of Johns Hopkins spinout Kala Pharmaceuticals (NASDAQ: KALA - ophthalmology). Robert was nominated as Biotech CEO of the Year at the World Vaccine Congress and was selected as one of the “100 of the Most Inspiring People” by PharmaVoice Magazine. He was Co-Founder of Lux Research and has served as an advisor to the Bill & Melinda Gates Foundation. Robert was also a member of Motorola’s Research Visionary Board and has been an invited lecturer or panelist at MIT, Stanford, Yale University, Brown, Memorial Sloan-Kettering Cancer Center, the National Cancer Institute, Georgetown, and the University of Virginia. He has been published in The Journal of Biomedical Materials Research and Nature Biotechnology. Robert graduated from the University of Virginia with a B.S. in Architecture and is a former member of the Regional Selection Committee for UVA’s Jefferson Scholars Foundation.
United States
San Francisco Bay Area
Venture Capital and Private Equity Principals
Venture Capital, Early-Stage Startups, Film Production, Entrepreneurship
Experience
chairman - audit committee
kala pharmaceuticals
advisor
bill & melinda gates foundation
chairman - audit committee
genocea biosciences
co-founder
forbes/wolfe emerging tech report
chief technology officer
vmdo architects
mentor
ucsf
Entrepreneurship Center (Startup 101 class mentor)
compensation committee
cala health
board of directors
kala pharmaceuticals
board of directors
cala health
advisor
university of virginia
board observer
visterra inc.
advisor - venture studio program
stanford graduate school of business
mentor - technology entrepreneurship
stanford university
Mentor / Judge for E145 -Technology Entrepreneurship course at Stanford
guest lecturer
stanford university
Guest speaker at E145 - Technology Entrepreneurship course
guest speaker
university of virginia
Guest speaker at David Touve’s ‘Startup’ (Entrepreneurship 101) class
judge - bases business plan competition
stanford university
As one of the premiere student-run entrepreneurship organizations in the world, BASES promotes entrepreneurship education at Stanford University in order to empower the next generation of entrepreneurs.
board of directors
genocea biosciences
co-founder and member of board of directors
lux research
chairman - nominating and governance committee
kala pharmaceuticals
chairman - audit committee
kyruus
board of directors
kyruus
founding chief executive officer
kala pharmaceuticals
Kala Pharmaceuticals is developing innovative ophthalmic treatments based on the company’s Mucosal Penetrating Product (MPP) platform. Kala’s products have an unprecedented ability to rapidly coat and effectively penetrate mucosal tissues resulting in superior therapeutic efficacy and transformative treatment outcomes for patients.
board observer
kyruus
co-founder and chief executive officer
mahana therapeutics
founding chief executive officer
genocea biosciences
Genocea Biosciences was founded in 2006 to commercialize key breakthroughs in vaccine discovery and development. When they work, vaccines are one of the most effective ways of preventing and treating disease. Unfortunately, many research and clinical vaccine programs are hit-and-miss because there is currently no way to screen all possible antigens or predict which ones will work. To remove the guesswork, we need the ability to mimic the human immune system in vitro so one can identify which antigenic epitopes will elicit a competent immune response. Genocea can rapidly identify antigens that result in the in vivo stimulation of protective CD8+ and CD4+ T-cells, targets that can be immediately incorporated into existing antigen delivery systems to produce multivalent vaccine formulations that have the highest probability of generating protective cell-mediated immunity.
co-founder and managing general partner
lux capital
Lux Capital is a venture capital firm that helps entrepreneurs turn breakthroughs into world-changing businesses within energy, healthcare and technology. We have offices in New York City and Menlo Park. The Lux Capital team has founded more than 20 companies from scratch.
Education
california state university channel islands
university of virginia
architecture
Robert Paull's Contact Information
Phone
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles
Find Emails
Access verified email addresses for your target contacts.
657M+ emails
Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers
More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.